Small-Cell Lung Cancer | Unmet Need | Extensive-Stage Small-Cell Lung Cancer | US/EU | 2023

MARKET OUTLOOK

Extensive-stage SCLC is an incurable disease for which very few treatment options exist. Platinum-based chemotherapy was the standard of care for these patients until the approval of immune checkpoint inhibitors—Tecentriq (Roche/Genentech) and Imfinzi (AstraZeneca)—changed the treatment paradigm for extensive-stage SCLC patients. The combination of immune checkpoint inhibitors with platinum agents dominates the first-line setting, but the clinical benefit of these regimens is limited. Treatment options are scarce in the recurrent setting, where poorly efficacious chemotherapeutic agents are mostly used. Despite recent advances, there is an urgent need for more-effective therapies that improve extensive-stage SCLC patients’ outcomes.

QUESTIONS ANSWERED

• What are the treatment drivers and goals influencing medical oncologists’ prescribing decisions for extensive-stage SCLC?
• How do current therapies, such as Tecentriq and Imfinzi, perform on key clinical attributes for these patients? How satisfied are physicians with the available therapies?
• What are the greatest unmet needs in extensive-stage SCLC? What are the most attractive opportunities for novel therapies in this setting?
• What trade-offs across key clinical attributes and price are U.S. and European medical oncologists willing to make for a new therapy to treat first-line extensive-stage SCLC?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 61 U.S. and 30 European medical oncologists fielded in November 2022

Key companies: Roche, Genentech, AstraZeneca

Key drugs: Tecentriq, Imfinzi, cytotoxic chemotherapy